Efficacy of Apremilast for Oral Ulcers Associated with Active Behcet's Syndrome over 28 Weeks: Results from a Phase III Study

dc.contributor.author	Yazici, Yusuf
dc.contributor.author	Cheng, Sue
dc.contributor.author	Paris, Maria
dc.contributor.author	Chen, Mindy
dc.contributor.author	Melikoglu, Melike
dc.contributor.author	Hatemi, Gulen
dc.contributor.author	McCue, Shannon
dc.contributor.author	Mahr, Alfred
dc.contributor.author	Ishigatsubo, Yoshiaki
dc.contributor.author	Song, Yeong Wook
dc.date.accessioned	2021-03-03T16:14:56Z
dc.date.available	2021-03-03T16:14:56Z
dc.identifier.citation	Hatemi G., Mahr A., Ishigatsubo Y., Song Y. W. , Melikoglu M., Cheng S., McCue S., Paris M., Chen M., Yazici Y., "Efficacy of Apremilast for Oral Ulcers Associated with Active Behcet's Syndrome over 28 Weeks: Results from a Phase III Study", ARTHRITIS & RHEUMATOLOGY, cilt.70, 2018
dc.identifier.issn	2326-5191
dc.identifier.other	vv_1032021
dc.identifier.other	av_433a5933-b080-4eb8-aae7-9c195c704b68
dc.identifier.uri	http://hdl.handle.net/20.500.12627/48905
dc.language.iso	eng
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	İmmünoloji ve Romatoloji
dc.subject	ROMATOLOJİ
dc.subject	Klinik Tıp
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.title	Efficacy of Apremilast for Oral Ulcers Associated with Active Behcet's Syndrome over 28 Weeks: Results from a Phase III Study
dc.type	Makale
dc.relation.journal	ARTHRITIS & RHEUMATOLOGY
dc.contributor.department	Celgene Corporation , ,
dc.identifier.volume	70
dc.contributor.firstauthorID	256406

Files in this item

Files	Size	Format	View
There are no files associated with this item.